Effectiveness of Cervical Transforaminal Epidural Steroid Injection
NCT04544683
Completed
Study Purpose: This study is intended to monitor outcomes for 1 year following cervical TFESI. Based on current clinic volume and enrollment rates into a current study of cervical epidural injections that is nearing completion, we conservatively estimate a study enrollment period of 18 months and a total period of 2.5 years from enrollment to final follow-up data collection. If the study were to theoretically start enrolling in July 2019, we would anticipate completion by February 2022. Object... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/16/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Cervical Radiculopathy, Cervical Spondylosis, Disk, Herniated
Register for Updates
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +35 locations
Conditions: COVID-19
Register for Updates
Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye
NCT04498468
Terminated
To determine efficacy and safety profile of dexamethasone 0.4mg lacrimal insert in dry eye related ocular surface inflammation.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/13/2024
Locations: Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Dry Eye
Register for Updates
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT02119468
Completed
This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple myeloma. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide and dexamethasone can modify and regulate the immune system and may stop cancer cells from growing. Giving ixazomib with pomalidomide... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Mayo Clinic, Scottsdale, Arizona +4 locations
Conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Register for Updates
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT03472573
Completed
This phase I trial studies the side effects and best dose of palbociclib when given together with dexamethasone in treating participants with B-cell acute lymphoblastic leukemia that has come back after a period of improvement or does not respond to treatment. Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a steroid medication that is used in combination with other medications to treat B-cell acute lymphoblastic leukemia.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Register for Updates
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
NCT03756896
Active Not Recruiting
This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, pomalidomid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Plasma Cell Myeloma
Register for Updates
Liposomal Bupivacaine in Shoulder Arthroscopy
NCT04461028
Withdrawn
Background: The research study is being conducted to see if using the liposomal Bupivacaine for the Interscalene block will improve the patient pain control and the whole patient's experience 48 hours after surgery when compared to using the regular Marcaine (bupivacaine hydrochloride) in addition to the dexamethasone. All preoperative, surgical, post-operative care in the recovery room, and discharge instructions will be the same as any other patient undergoing this surgery. Study procedures... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Rotator Cuff Tears
Register for Updates
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
NCT00381680
Completed
This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giv... Read More
Gender:
ALL
Ages:
Between 1 year and 29 years
Trial Updated:
03/04/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +172 locations
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
Register for Updates
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
NCT04514029
Active Not Recruiting
Open-label, single-arm, single center pilot study to assess safety and feasibility of administering dexamethasone intrathecally and simvastatin orally during axicabtagene ciloleucel (axi-cel) treatment. Feasibility will be measured by the proportion of patients completing two-thirds (2/3) of their assigned treatments. The study will be deemed feasible if 2/3 or more of the patients complete 2/3 or more of their allocated treatments.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/23/2024
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Lymphoma
Register for Updates
Dexamethasone for Migraine - Dose Comparison
NCT04112823
Completed
Dexamethasone is an evidence-based treatment of acute migraine. This is a randomized comparison of two different doses of dexamethasone for acute migraine. All patients will also be treated with metoclopramide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Migraine
Register for Updates
Treating Respiratory Emergencies in Children Study
NCT06074185
Recruiting
Over 200,000 children have a 911 Emergency Medical Services (EMS) activation for respiratory distress each year, most of whom have acute wheezing. Early treatment in the prehospital setting could more rapidly relieve respiratory distress symptoms, prevent hypoxia, reduce invasive interventions, and reduce the need to be hospitalized, thereby facilitating earlier return to normal daily activities. Preliminary data from one site found hospital admission was reduced from 30% to 21% among children w... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/22/2024
Locations: University at Buffalo, Buffalo, New York +2 locations
Conditions: Asthma in Children
Register for Updates
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
NCT03817320
Active Not Recruiting
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/20/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California +17 locations
Conditions: ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Register for Updates